Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Biopharma gathers in London as M&A shines but China clouds loom
Executives and investors at London Life Sciences Week reflected on a busy year for M&A while weighing the potential impact of the COINS Act.
James Waldron
Nov 20, 2026 8:40am
Merck’s TROP2 ADC extends survival in pivotal cancer trial
Nov 20, 2026 11:20am
Researchers uncover plastics in brains of patients with dementia
Nov 20, 2026 9:20am
FDA delays Belite’s eye disease pill decision by 3 months
Nov 20, 2026 9:08am
Teva loses R&D head amid innovation revamp—Chutes & Ladders
Nov 20, 2026 8:30am
Bausch + Lomb and Celldex rocked by respective ph. 2 flops
Nov 20, 2026 5:20am
More News
Anthropic director Vas Narasimhan bets AI can speed Novartis R&D
Nov 19, 2026 5:31pm
Crown stays put as $204M Adicon deal falls through
Nov 19, 2026 4:55pm
Evaxion halts infectious disease work in R&D refocus on oncology
Nov 19, 2026 10:02am
nChroma halves headcount, halts trial of potential HBV ‘cure’
Nov 19, 2026 9:08am
See more stories